Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Fajgenbaum

Showing results (51-60 of 114) with videos related to

Pageof 12
Sort By:
Nature Reviews. Disease Primers|November 26, 2021
Castleman diseaseAntonino Carbone, Margaret Borok, Blossom Damania, et al.
Annals of Hematology|May 8, 2018
Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman diseaseYujun Dong, Lu Zhang, Lin Nong, et al.
British Journal of Haematology|February 15, 2024
Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survivalYu-Han Gao, Yan-Ting Liu, Miao-Yan Zhang, et al.
Leukemia & Lymphoma|February 1, 2022
A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCDLu Zhang, Miao-Yan Zhang, Xin-Xin Cao, et al.
Leukemia|September 29, 2022
Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric castleman disease: a population-level US health claims analysisSudipto Mukherjee, Karan Kanhai, David Kauffman, et al.
Acta Oncologica (Stockholm, Sweden)|February 16, 2019
Letter to the editor regarding 'Non-cirrhotic portal hypertension associated with multicentric Castleman's disease: a case report'Dale M Kobrin, Ana Luisa Pinto, Sophia T Parente, et al.
Leukemia|December 16, 2022
Correction to: Organ dysfunction, thrombotic events, and malignancies in patients with idiopathic multicentric Castleman disease: a population-level US health claims analysisSudipto Mukherjee, Karan Kanhai, David Kauffman, et al.
Frontiers in Immunology|August 5, 2022
Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modellingJean-François Rossi, Hao-Chun Chiang, Zhao-Yang Lu, et al.
Frontiers in Medicine|October 12, 2017
TAFRO Syndrome in Caucasians: A Case Report and Review of the LiteratureCéline Louis, Sandrine Vijgen, Kaveh Samii, et al.
British Journal of Haematology|September 12, 2018
Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial dataDeanna E Morra, Sheila K Pierson, Dustin Shilling, et al.
Pageof 12

Showing results (51-60 of 114) with videos related to

Sort By:
Pageof 12
Nature Reviews. Disease Primers|November 26, 2021
Castleman diseaseAntonino Carbone, Margaret Borok, Blossom Damania, et al.
Annals of Hematology|May 8, 2018
Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman diseaseYujun Dong, Lu Zhang, Lin Nong, et al.
British Journal of Haematology|February 15, 2024
Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survivalYu-Han Gao, Yan-Ting Liu, Miao-Yan Zhang, et al.
Leukemia & Lymphoma|February 1, 2022
A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCDLu Zhang, Miao-Yan Zhang, Xin-Xin Cao, et al.
Leukemia|September 29, 2022
Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric castleman disease: a population-level US health claims analysisSudipto Mukherjee, Karan Kanhai, David Kauffman, et al.
Acta Oncologica (Stockholm, Sweden)|February 16, 2019
Letter to the editor regarding 'Non-cirrhotic portal hypertension associated with multicentric Castleman's disease: a case report'Dale M Kobrin, Ana Luisa Pinto, Sophia T Parente, et al.
Leukemia|December 16, 2022
Correction to: Organ dysfunction, thrombotic events, and malignancies in patients with idiopathic multicentric Castleman disease: a population-level US health claims analysisSudipto Mukherjee, Karan Kanhai, David Kauffman, et al.
Frontiers in Immunology|August 5, 2022
Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modellingJean-François Rossi, Hao-Chun Chiang, Zhao-Yang Lu, et al.
Frontiers in Medicine|October 12, 2017
TAFRO Syndrome in Caucasians: A Case Report and Review of the LiteratureCéline Louis, Sandrine Vijgen, Kaveh Samii, et al.
British Journal of Haematology|September 12, 2018
Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial dataDeanna E Morra, Sheila K Pierson, Dustin Shilling, et al.
Pageof 12